Combination antiviral therapy for CMV in kidney transplant
Treatments studied
Part of Infections clinical trials.
This trial tests a combination of two antiviral drugs (letermovir and valganciclovir) to treat CMV infections in kidney transplant recipients. It aims to find a safer, more effective treatment option for people with active CMV after transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have received a kidney transplant.
- You have a CMV infection with a high viral load (at least 3000 IU/mL in two tests or at least 30000 IU/mL in one test).
- Your doctor believes you can take the oral medication valganciclovir.
- You are not currently taking strong medications that could interfere with the study drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two strategies to prevent a viral infection called CMV after kidney transplant. It tests whether an “immune-guided” approach (using your immune test results) can prevent CMV as well as or better than giving preventive antiviral medicine to everyone.
This trial tests two ways to prevent CMV in kidney transplant patients who are at high risk. It compares giving antiviral medicine preemptively (based on regular blood tests) versus giving it as prophylaxis (starting right after transplant). The goal is to see which approach prevents CMV infection better.
This study compares two antiviral medications to prevent CMV (a common virus that can cause problems after kidney transplant) in people who had the virus before their transplant. The goal is to see which medicine works better and is safer for preventing CMV disease.
This trial tests a new medicine, Leymovir, against a standard one, Valganciclovir, to prevent a common virus infection (CMV) after a first kidney transplant. It may help you avoid CMV-related illness.
This trial compares two antiviral drugs, valacyclovir and valganciclovir, to see if valacyclovir works as well as valganciclovir for preventing CMV and EBV infections after a kidney transplant.
This trial tests whether giving CMV immunoglobulin (an antibody medicine) after transplant can help prevent a serious CMV infection in people who receive a kidney or liver from a CMV-positive donor. You might be eligible if you are getting one of these transplants and are at high risk for CMV.
Hear when a new Cytomegalovirus Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.